Citigroup’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.8M | Buy |
56,016
+24,844
| +80% | +$7.42M | 0.01% | 1153 |
|
|
2026
Q1 | $8.05M | Buy |
31,172
+1,229
| +4% | +$327K | ﹤0.01% | 1607 |
|
|
2025
Q4 | $7.38M | Buy |
29,943
+20,293
| +210% | +$4.27M | ﹤0.01% | 1747 |
|
|
2025
Q3 | $1.7M | Sell |
9,650
-42,883
| -82% | -$6.42M | ﹤0.01% | 2803 |
|
|
2025
Q2 | $7.22M | Sell |
52,533
-20,992
| -29% | -$3.08M | ﹤0.01% | 1609 |
|
|
2025
Q1 | $13.3M | Sell |
73,525
-26,108
| -26% | -$4.39M | 0.01% | 1190 |
|
|
2024
Q4 | $15.6M | Buy |
99,633
+64,549
| +184% | +$11.5M | 0.01% | 1109 |
|
|
2024
Q3 | $6.39M | Buy |
35,084
+13,874
| +65% | +$2.68M | ﹤0.01% | 1649 |
|
|
2024
Q2 | $3.9M | Sell |
21,210
-30,908
| -59% | -$5.19M | ﹤0.01% | 1821 |
|
|
2024
Q1 | $9.27M | Buy |
52,118
+15,552
| +43% | +$2.16M | 0.01% | 1297 |
|
|
2023
Q4 | $4.54M | Buy |
36,566
+779
| +2% | +$86.4K | ﹤0.01% | 1657 |
|
|
2023
Q3 | $4.15M | Buy |
35,787
+13,423
| +60% | +$1.64M | ﹤0.01% | 1542 |
|
|
2023
Q2 | $2.63M | Sell |
22,364
-28,221
| -56% | -$2.88M | ﹤0.01% | 1964 |
|
|
2023
Q1 | $4.05M | Buy |
50,585
+21,825
| +76% | +$1.71M | ﹤0.01% | 1611 |
|
|
2022
Q4 | $2.28M | Sell |
28,760
-21,063
| -42% | -$1.56M | ﹤0.01% | 1934 |
|
|
2022
Q3 | $3.47M | Buy |
49,823
+12,806
| +35% | +$925K | ﹤0.01% | 1766 |
|
|
2022
Q2 | $2.43M | Buy |
37,017
+21,785
| +143% | +$1.36M | ﹤0.01% | 1986 |
|
|
2022
Q1 | $1.01M | Sell |
15,232
-19,656
| -56% | -$1.23M | ﹤0.01% | 2937 |
|
|
2021
Q4 | $2.44M | Buy |
34,888
+4,926
| +16% | +$287K | ﹤0.01% | 2449 |
|
|
2021
Q3 | $1.56M | Sell |
29,962
-19,413
| -39% | -$1.15M | ﹤0.01% | 2735 |
|
|
2021
Q2 | $3.36M | Buy |
49,375
+10,456
| +27% | +$730K | ﹤0.01% | 2258 |
|
|
2021
Q1 | $3M | Buy |
38,919
+17,244
| +80% | +$1.25M | ﹤0.01% | 2205 |
|
|
2020
Q4 | $1.3M | Buy |
21,675
+19,943
| +1,151% | +$996K | ﹤0.01% | 3275 |
|
|
2020
Q3 | $75K | Sell |
1,732
-32,489
| -95% | -$1.41M | ﹤0.01% | 5323 |
|
|
2020
Q2 | $1.42M | Sell |
34,221
-25,488
| -43% | -$1.23M | ﹤0.01% | 3181 |
|
|
2020
Q1 | $2.58M | Sell |
59,709
-1,060
| -2% | -$55.4K | ﹤0.01% | 2248 |
|
|
2019
Q4 | $3.37M | Buy |
60,769
+46,937
| +339% | +$2.3M | ﹤0.01% | 2402 |
|
|
2019
Q3 | $481K | Buy |
13,832
+11,377
| +463% | +$509K | ﹤0.01% | 4369 |
|
|
2019
Q2 | $99K | Sell |
2,455
-19,659
| -89% | -$643K | ﹤0.01% | 5881 |
|
|
2019
Q1 | $728K | Buy |
22,114
+11,811
| +115% | +$278K | ﹤0.01% | 3750 |
|
|
2018
Q4 | $214K | Buy |
+10,303
| New | +$216K | ﹤0.01% | 4959 |
|
Other funds holding KRYS
ACA
SCM
Citigroup's KRYS Position: Q2 2026 in Review
Citigroup increased its Krystal Biotech (KRYS) stake by 80% in Q2 2026, buying an estimated $7.42M and bringing the position to 56,016 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1153.
Citigroup first reported a position in KRYS in Q4 2018 and has held it in 31 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Citigroup held 56,016 shares of Krystal Biotech worth $20.8M as of Q2 2026.
- Citigroup bought 24,844 Krystal Biotech shares in Q2 2026, an estimated $7.42M.
- Krystal Biotech made up 0.01% of Citigroup's portfolio in Q2 2026, its #1153 holding.
- Citigroup first reported a position in Krystal Biotech in Q4 2018 and has held it in 31 quarters since.
- 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.